B. Riley Securities Reiterates Buy on Capricor Therapeutics, Raises Price Target to $50

Benzinga · 2d ago
B. Riley Securities analyst Madison El-Saadi reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $21 to $50.